Bioaffinity Technologies Warrant Stock Today
| BIAFW Stock | USD 0.61 0.31 103.33% |
Performance0 of 100
| Odds Of DistressOver 85
|
BioAffinity Technologies is selling for under 0.61000001 as of the 30th of January 2025; that is 103.33 percent up since the beginning of the trading day. The stock's lowest day price was 0.3. BioAffinity Technologies has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 31st of December 2024 and ending today, the 30th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of September 2022 | Category Healthcare | Classification Health Care |
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company was founded in 2014 and is based in San Antonio, Texas. Bioaffinity Technologies operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. More on bioAffinity Technologies Warrant
Moving together with BioAffinity Stock
Moving against BioAffinity Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
BioAffinity Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BioAffinity Technologies can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioAffinity Technologies' financial leverage. It provides some insight into what part of BioAffinity Technologies' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
bioAffinity Technologies Warrant (BIAFW) is traded on NASDAQ Exchange in USA. It is located in 22211 West Interstate 10, San Antonio, TX, United States, 78257 and employs 75 people. BioAffinity Technologies is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
bioAffinity Technologies Warrant has accumulated about 214.4 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08.
Check BioAffinity Technologies Probability Of Bankruptcy
BioAffinity Technologies Historical Income Statement
BioAffinity Stock Against Markets
BioAffinity Technologies Corporate Management
| Timothy JD | Secretary VP | Profile | |
| Dallas Coleman | National Sales | Profile | |
| William Bauta | Senior Therapeutics | Profile | |
| Maria JD | President, Founder | Profile | |
| Xavier MS | VP Operations | Profile |
Additional Tools for BioAffinity Stock Analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.